ClinicalTrials.gg
CompletedNCT03918018Updated Apr 17, 2019

BiOSENCY BORA Band SpO2 Validation Study

An interventional study of BORA Band SpO2 Validation Study in Hypoxia, sponsored by Biosency. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Biosency · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 269 studies in Hypoxia with a site in United States — 36 open to participants now, 51 under way, 2 of them phase 3. Hypoxia · United States.

Enrollment
152nd of 181
10 · median 30
Started
2019
with 9 others
No phase
110 of 269
15 open now
Registered
127th of 269
by date

Among the 269 studies in Hypoxia with a site in United States, this one is the 152nd largest by enrollment of the 181 interventional ones that give a count, is one of 10 that started in 2019, is one of 110 with no phase, and was the 127th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

36 of the 269 studies in Hypoxia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Hypoxia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to validate the SpO2 accuracy of the BiOSENCY BORA BAND™ wristband Pulse Oximeter during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. The end goal is to provide supporting documentation for the SpO2 accuracy validation of BORA BAND™ wristband Pulse Oximeter.

It is required that the Accuracy Root Mean Square (ARMS) performance of the BORA BAND™ wristband Pulse Oximeter will meet a specification of 3.5 or better in non-motion conditions for the range of 70 - 100% SpO2 thereby demonstrating an acceptable SpO2 accuracy performance specification.

Read the detailed description

The SpO2 accuracy performance of BiOSENCY BORA BAND™ wristband Pulse Oximeter will be evaluated during non-motion conditions over the range of 70-100% SaO2 and compared to arterial blood samples assessed by CO-Oximetry. A minimum of 10 healthy adult male and female subjects, ranging in age and pigmentation from light to dark, will be enrolled in the study to meet the study design requirements defined by ISO 80601-2-61:2017 and by the FDA's Guidance for Pulse Oximeters (March 4, 2013). The subjects will have an arterial catheter placed in the radial artery to allow for simultaneous blood samples during stable plateaus of induced hypoxic levels. The investigational device will be placed on the wrist opposite for the test per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.

For the data analysis, the control oximeter will be used to assess the stability of each data point. Data that is found to be unstable will be removed prior to the comparative analysis. The CO-Oximeter data will be reviewed to make sure it does not contain any anomalous values such as elevated, low or inconsistent COHb, MetHb, or tHb data. Anomalous values will be removed from the analysis prior to pairing of the SpO2 and SaO2 data. The statistical analysis is performed on a minimum of 200 data points collected from at least 10 subjects for the range of 70% to 100% SaO2 with allowance of ± 3% of the target range. Functional SaO2 as measured by Reference CO-Oximetry will be used as the basis for comparison. The Accuracy Root Mean Square (ARMS) calculation is used to determine the SpO2 accuracy performance. Success will be achieved with an ARMS of 3.5 or better showing equivalence to the Gold Standard Reference CO-Oximetry providing documentation to support SpO2 accuracy claims for the investigational device.

The study population will include 10-15 healthy non-smoking (or has refrained from smoking for 2 days) competent adults, 18-50 years of age. The subject selection will be an equitable distribution of males and females of any race with varying skin tones including at least 2 darkly pigmented subjects or 15% of the subject pool, whichever is larger. The subjects must understand the study and consent to participate by signing the Informed Consent Form. The subjects must be healthy showing no evidence of medical problems as indicated by satisfactorily completing the health assessment form.

03

Conditions studied

  • Hypoxia

Browse trials for

Keywords

  • Pulse oximetry
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
  • Subject must have the ability to understand and provide written
  • Subject is 18 to 50 years of age
  • Subject must be willing and able to comply with study procedures and duration
  • Subject is a non-smoker or who has not smoked within 2 days prior to the study
  • Wrist size should be between 15-23 cm (5.9 - 9 inches)

Exclusion criteria

Exclusion Criteria:

  • Subject is considered as being morbidly obese (defined as >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of ).
  • Smoker Subjects who have refrained will be screened for COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
  • Subjects with known respiratory conditions such as: (self-reported)

    • uncontrolled / severe asthma,
    • flu,
    • pneumonia / bronchitis,
    • shortness of breath / respiratory distress,
    • unresolved respiratory or lung surgery with continued indications of health issues ,
    • emphysema, , lung disease
  • Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and review)

    • hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during health screen).
    • have had cardiovascular surgery
    • Chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure (CHF)
    • history of stroke
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • cardiomyopathy
  • Self-reported health conditions as identified in the Health Assessment Form (self-reported)

    • diabetes,
    • uncontrolled thyroid disease,
    • kidney disease / chronic renal impairment,
    • history of seizures (except childhood febrile seizures),
    • epilepsy,
    • history of unexplained syncope,
    • recent history of frequent migraine headaches,
    • recent symptomatic head injury (within the last 2 months)
    • cancer / chemotherapy
  • Subjects with known clotting disorders (self-reported)

    • history of bleeding disorders or personal history of prolonged bleeding from injury
    • history of blood clots
    • hemophilia
    • current use of blood thinner: prescription or daily use of aspirin
  • Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
  • Subjects with severe allergies to iodine (only applicable if iodine is used)
  • Subjects with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
  • Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \< 0.4)
  • Unwillingness or inability to remove colored nail polish from test digits.
  • Other known health condition, should be considered upon disclosure in health assessment form
  • Wrist size should be between 15-23 cm (5.9 - 9 inches)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Interventions

  • DeviceBORA Band SpO2 Validation Study

    Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk. Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%. The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects.

06

What researchers measure

Primary outcomes

  1. Accuracy of BORA Band SpO2 measurements versus arterial blood co-oximetry

    Accuracy of the BORA Band SpO2 measurement as compared to reference co-oximetry performed on arterial blood samples. Results shall include * SpO2 Root mean square accuracy of BORA Band * SpO2 Bias of BORA Band * Bland-Altman plots with linear regression line and 95% upper and lower limits of agreement

    Time frame: 1 day

  2. Accuracy of BORA Band Pulse Rate measurements versus electrocardiogram readings

    Accuracy of the BORA Band pulse rate measurement as compared to reference electrocardiogram readings. Results shall include * Pulse rate Root mean square accuracy of BORA Band * Pulse rate Bias of BORA Band

    Time frame: 1 day

07

Study locations

1 site
  • Clinimark Desaturation Laboratory
    Louisville, Colorado 80027, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Feb 2019, 0 months.

Of 30 industry-sponsored interventional studies with no phase under Hypoxia, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 6. This study's 0 months is below that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2019
First posted
Apr 17, 2019
StartActual
Feb 19, 2019
Primary completionActual
Feb 21, 2019
CompletionActual
Feb 21, 2019
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03918018
Lead sponsor
Biosency
Collaborators
Clinimark, LLC
Responsible party
Sponsor
First posted
Apr 17, 2019
Start date
Feb 19, 2019
Primary completion
Feb 21, 2019
Completion
Feb 21, 2019
Last update
Apr 17, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion